Liu Bing, Xu Yu-Jie, Chu Feng-Ran, Sun Guang, Zhao Guo-Dong, Wang Sheng-Zhong
Department of Gastrointestinal Surgery, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou 570208, Hainan Province, China.
Clinical College, Hainan Medical University, Haikou 571199, Hainan Province, China.
World J Gastrointest Surg. 2024 Feb 27;16(2):396-408. doi: 10.4240/wjgs.v16.i2.396.
The efficacy of neoadjuvant chemotherapy (NAC) in advanced gastric cancer (GC) is still a controversial issue.
To find factors associated with chemosensitivity to NAC treatment and to provide the optimal therapeutic strategies for GC patients receiving NAC.
The clinical information was collected from 230 GC patients who received NAC treatment at the Central South University Xiangya School of Medicine Affiliated Haikou Hospital from January 2016 to December 2020. Least absolute shrinkage and selection operator logistic regression analysis was used to find the possible predictors. A nomogram model was employed to predict the response to NAC.
In total 230 patients were finally included in this study, including 154 males (67.0%) and 76 females (33.0%). The mean age was (59.37 ± 10.60) years, ranging from 24 years to 80 years. According to the tumor regression grade standard, there were 95 cases in the obvious response group (grade 0 or grade 1) and 135 cases in the poor response group (grade 2 or grade 3). The obvious response rate was 41.3%. Least absolute shrinkage and selection operator analysis showed that four risk factors significantly related to the efficacy of NAC were tumor location ( < 0.001), histological differentiation ( = 0.001), clinical T stage ( = 0.008), and carbohydrate antigen 724 ( = 0.008). The C-index for the prediction nomogram was 0.806. The calibration curve revealed that the predicted value exhibited good agreement with the actual value. Decision curve analysis showed that the nomogram had a good value in clinical application.
A nomogram combining tumor location, histological differentiation, clinical T stage, and carbohydrate antigen 724 showed satisfactory predictive power to the response of NAC and can be used by gastrointestinal surgeons to determine the optimal treatment strategies for advanced GC patients.
新辅助化疗(NAC)在晚期胃癌(GC)中的疗效仍是一个有争议的问题。
寻找与NAC治疗化疗敏感性相关的因素,并为接受NAC治疗的GC患者提供最佳治疗策略。
收集2016年1月至2020年12月在中南大学湘雅医学院附属海口医院接受NAC治疗的230例GC患者的临床信息。采用最小绝对收缩和选择算子逻辑回归分析来寻找可能的预测因素。采用列线图模型预测对NAC的反应。
本研究最终纳入230例患者,其中男性154例(67.0%),女性76例(33.0%)。平均年龄为(59.37±10.60)岁,范围为24岁至80岁。根据肿瘤退缩分级标准,明显缓解组(0级或1级)95例,缓解不佳组(2级或3级)135例。明显缓解率为41.3%。最小绝对收缩和选择算子分析显示,与NAC疗效显著相关的四个危险因素为肿瘤位置(<0.001)、组织学分化(=0.001)、临床T分期(=0.008)和糖类抗原724(=0.008)。预测列线图的C指数为0.806。校准曲线显示预测值与实际值具有良好的一致性。决策曲线分析表明列线图在临床应用中具有良好的价值。
结合肿瘤位置、组织学分化、临床T分期和糖类抗原724的列线图对NAC反应显示出令人满意的预测能力,胃肠外科医生可用于确定晚期GC患者的最佳治疗策略。